Brief: Inmune Bio Inc Entered Into Additional Amendment To Inkmune Agreement

Inmune Bio

20/04/2023 22:05

April 20 (Reuters) - INmune Bio Inc  INMB.O :
    * INMUNE BIO INC - ON APRIL 17, ENTERED INTO ADDITIONAL
AMENDMENT
TO INKMUNE AGREEMENT TO REMOVE DUE DILIGENCE REQUIREMENTS OF
INKMUNE LICENSE AGREEMENT
    * INMUNE BIO INC - ON APRIL 17, ENTERED SECOND AMENDMENT TO
EXCLUSIVE LICENSE AGREEMENT TO PITT AGREEMENT
    * INMUNE BIO INC - UNDER SECOND PITT AMENDMENT DOSE OF FIRST
PATIENT IN A PHASE II CLINICAL TRIAL WOULD OCCUR BY JUNE 26,
2026
    * INMUNE BIO INC - UNDER SECOND PITT AMENDMENT REQUIREMENT
TO
OBTAIN MARKETING AUTHORIZATION FROM FDA OR FOREIGN EQUIVALENT BY
JUNE 26, 2031


Further company coverage:  INMB.O 

 ((Reuters.Briefs@thomsonreuters.com;))